Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
Conclusion The RP2D of metformin in combination with carboplatin and paclitaxel in advanced ovarian cancer is 1000 mg tds. This is higher than the RP2D reported for combination with targeted agents. A potential PK interaction of metformin with carboplatin was identified.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chemotherapy | Diabetes | Drugs & Pharmacology | Endocrinology | Epidemiology | Epithelial Cancer | Fortamet | Investigational New Drugs | Metformin | Ovarian Cancer | Ovaries | Palliative | Study | Thrombocytopenia | Toxicology